A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta
BackgroundAgalsidase beta is used to treat Fabry disease (FD); however, data on cardiac and cerebrovascular outcomes with agalsidase beta treatment come from studies with limited numbers of patients.MethodsA systematic literature review of studies reporting on the efficacy and effectiveness of agals...
Saved in:
Main Authors: | Gavin Y. Oudit, Pronabesh DasMahapatra, Nicole Lyn, Florence R. Wilson, Adekemi Adeyemi, Chae Sung Lee, Ana Crespo, Mehdi Namdar |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1415547/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
by: Christoph Wanner, et al.
Published: (2020-06-01) -
Fabry cardiomyopathy: Gb3‐induced auto‐reactive panmyocarditis requiring heart transplantation
by: Andrea Frustaci, et al.
Published: (2020-06-01) -
Anxiety-like behavior and altered hippocampal activity in a transgenic mouse model of Fabry disease
by: Kai Kummer, et al.
Published: (2025-02-01) -
Silicon photonic modulators with a 2 × 1 Fabry–Perot cavity
by: Cao Hengzhen, et al.
Published: (2025-01-01) -
Clinical characteristics of female Fabry disease patients with hypertrophic cardiomyopathy with mid-ventricular obstruction
by: Natsuko Inagaki, et al.
Published: (2025-03-01)